$7 Billion Parkinson’s Disease Market by 2033: Implications for Regulatory Scope

Market Overview and Growth Drivers

The PD therapeutics market is projected to grow at a compound annual growth rate (CAGR) of 7.6%, reaching $7 billion by 2033 in the seven major markets. This growth is fueled by eight late-stage pipeline products anticipated to be launched during the forecast period, addressing both motor symptoms and disease modification. 

Symptomatic treatments for motor symptoms expected to drive sales include: 

• NeuroDerm’s ND-0612 (carbidopa + levodopa) 

• AbbVie’s tavapadon 

• Pharma Two B’s P2B001 

• Cerevance’s solengepras 

• PharmaTher Holdings’ Ketarx 

Together, these products are forecast to contribute $1.6 billion in sales by 2033. 

Non-motor symptom treatments are less represented, with Anavex’s blarcamesine as the sole late-stage therapy targeting conditions such as PD dementia. Other candidates in this category have been discontinued due to development challenges. 

Disease-modifying therapies (DMTs) targeting α-synuclein aggregates include Roche’s prasinezumab and Annovis Bio’s buntanetap. While pivotal trial results have been

mixed, exploratory data suggests potential neuroprotective benefits. Combined sales for these DMTs are projected to reach $597.5 million globally by 2033. 

Cell therapy innovations are also advancing. BlueRock Therapeutics’ bemdaneprocel, currently in Phase III trials (exPDite-2 [NCT06944522]), involves the transplantation of dopaminergic neuronal progenitor stem cells into the brain, aiming to halt disease progression. 

Although patent expirations for key branded drugs may lead to increased generic competition, new product launches are expected to counterbalance market erosion and sustain growth. 

Why It Matters

This forecast reflects a robust innovation cycle in neurology, signaling opportunities for CNS drug developers to expand their portfolios. The growing focus on disease modification and cell-based approaches represents a shift toward treatments that go beyond symptom management, potentially improving long-term outcomes for PD patients. 

Relevant Stakeholders 

This update is particularly relevant for regulatory affairs teams, commercial strategists, business development executives, and R&D teams engaged in neurology and CNS drug development. 

Next Steps

Stakeholders should monitor the progress of late-stage candidates, competitive launches, and key patent expirations to inform long-term positioning strategies. Engagement in research collaborations and readiness for licensing or partnership opportunities may provide strategic advantage as the market evolves. While keeping track of market dynamics is essential, navigating the complex and fast-changing regulatory environment requires equally robust support.

RegASK is an AI-driven Agentic Solution for Regulatory Intelligence and Workflow Orchestration that helps life sciences and pharmaceutical companies stay ahead of constantly changing regulations through timely global regulatory monitoring, smart documentation, curated alerts and compliance insights.

FAQs

The market is projected to grow at a CAGR of 7.6%, reaching $7 billion by 2033.

Roche’s prasinezumab and Annovis Bio’s buntanetap are the two primary late-stage therapies targeting α-synuclein aggregates.

Bemdaneprocel is in Phase III trials (exPDite-2 [NCT06944522]) and is being investigated as a cell therapy for Parkinson’s disease.